CCSD code 0037G: Mdm2 gene amplification test guide

Key Takeaways

CCSD code 0037G identifies Mdm2 gene amplification testing, a pathology and diagnostic investigation code within the UK private healthcare billing schedule maintained by the Clinical Coding and Schedule Development Group (CCSD).

The test looks for extra copies of the MDM2 gene, a finding pathologists use to confirm certain soft-tissue tumors rather than as a general cancer screen.

Bupa, AXA Health, Vitality, and Aviva all recognize CCSD codes for reimbursement, though genetic and molecular pathology tests usually need pre-authorization before the sample is even taken.

Practice management software like Pabau helps UK private practices attach the correct CCSD code to a patient record and track a claim through to payment.

CCSD code 0037G identifies Mdm2 gene amplification testing, a pathology and diagnostic investigation code used within the UK private healthcare sector. Practices and laboratories use it to bill major insurers, including Bupa, AXA Health, Vitality, and Aviva, whenever this genetic or molecular test is requested for a patient.

This guide covers what MDM2 amplification testing actually detects, where the code sits within the CCSD schedule, and how to get a claim through an insurer’s system without it bouncing back.

What CCSD code 0037G identifies

CCSD code 0037G sits within the pathology and diagnostics side of the Clinical Coding and Schedule Development (CCSD) schedule, the system UK private medical insurers use to price and reimburse clinical services outside the NHS.

Rather than describing a surgical procedure, it identifies a specific laboratory test: Mdm2 gene amplification analysis, ordered when a pathologist needs to confirm whether a tissue sample carries extra copies of the MDM2 gene.

Genetic and molecular pathology codes work differently from procedural ones. There’s no incision, no operating room time, no recovery period to document. The billing event is a laboratory result, and the clinical narrative behind the claim comes from the requesting clinician and the reporting lab rather than an operation note.

The CCSD schedule itself sits behind a login at ccsd.org.uk, so billing teams should still confirm the current wording and fee band for 0037G directly against the schedule before submitting a claim. Descriptions and reimbursement brackets get revised periodically, and the CCSD Technical Guide (October 2025 edition) sets out the current business rules for pathology codes.

A quick way to see how 0037G compares with other genetic and molecular test codes on the same schedule:

What Mdm2 gene amplification testing actually involves

MDM2 is a gene that, at normal copy number, helps keep cell growth in check by regulating a well-known tumor-suppressor protein called p53. When a cell picks up extra copies of MDM2 (amplification, in genetics terms), that regulation gets overwhelmed, and the balance tips toward uncontrolled growth.

Here’s a scenario that shows why the test matters in practice. A patient in their 50s or 60s comes in with a slow-growing, painless lump in the thigh or deep in the abdomen. On a scan, and even under a microscope, it can look reassuringly like an ordinary lipoma, a benign fatty lump. The problem is that a low-grade liposarcoma can look almost identical at first glance.

The two are managed very differently. One needs monitoring or simple removal, while the other needs a wider surgical margin and closer follow-up. MDM2 amplification testing, usually run by fluorescence in situ hybridization (FISH), is what settles the question. Well-differentiated and dedifferentiated liposarcomas reliably carry the extra MDM2 copies. Ordinary lipomas don’t.

That’s the clinical reason this test gets ordered so often as part of a soft-tissue tumor work-up. It’s less about screening broadly for cancer and more about telling two look-alike diagnoses apart when the difference genuinely changes how a patient is treated.

Where 0037G sits in the CCSD schedule

The CCSD schedule splits broadly into a procedural side, covering surgical and interventional acts, and a pathology and diagnostics side, covering laboratory and genetic testing. Code 0037G belongs to the second group.

• Load it correctly: Add 0037G to your laboratory or pathology test code table, not the surgical procedure list many practice management systems keep separately.
• Match the narrative: Keep the test description in your system worded exactly as the schedule states it, since insurers cross-reference the two whenever a claim gets queried.
• Don’t assume from the format: A numeric-plus-letter code alone doesn’t tell you which chapter it belongs to. Y3811, for example, sits in a completely different part of the schedule despite a superficially similar structure.

Which insurers pay out on CCSD code 0037G

All the major UK private medical insurers build their fee schedules around CCSD codes, whether the code sits in the procedural chapters or the pathology and diagnostics side of the schedule. That said, each insurer applies its own rules on pre-authorization, bundling, and reimbursement rates for laboratory and genetic tests specifically.

• Bupa: Recognizes CCSD codes as standard. Check the Bupa code search portal to confirm 0037G is listed and to see the applicable fee band before invoicing.
• AXA Health: Processes claims through its specialist procedure and pathology code portal. Genetic and molecular tests typically need pre-authorization before the sample is collected.
• Vitality Health: Uses CCSD-based fees and offers a fee finder tool so practitioners can look up reimbursement by code before treatment.
• Aviva: Bases its fee schedule on CCSD codes, published and updated periodically. Verify current rates before quoting a patient a figure.
• Healix: Applies CCSD-based fees with its own unbundling guidelines. Review the Healix fee schedule before submitting to avoid bundling-related rejections.
• WPA, Allianz Care, and Cigna UK: All use CCSD coding as the basis for their fee schedules, though each has its own pre-authorization thresholds for pathology and genetic testing.

Reimbursement for 0037G will vary by insurer and contract year, so never quote a patient a fixed figure before checking the current schedule. For a deeper look at how one major insurer structures its fee schedule, see the Bupa CCSD codes guide.

Documentation a CCSD code 0037G claim needs

Claims for genetic pathology codes rarely get rejected because the code itself doesn’t exist. They get rejected because the supporting documentation doesn’t match what the insurer expects to see on file.

• Requesting clinician’s name and GMC or GDC registration number
• Date the specimen was collected and the clinical indication for testing
• Specimen type and sample reference or accession number
• Confirmation of the accredited laboratory that performed the Mdm2 gene amplification test
• Test narrative matching the CCSD code description exactly
• Patient name, date of birth, and insurer membership number
• Pre-authorization reference number, where the insurer requires one
• The pathologist’s result report, attached to the billing record

UK private healthcare providers are also subject to UK GDPR obligations around how long these records are retained. A GDPR documentation checklist for UK practices can help make sure your record-keeping meets both insurer and regulatory expectations at the same time, and standardized digital intake forms keep specimen and requesting-clinician details consistent across every genetic test ordered, rather than relying on whoever filled in the paperwork that day.

Submit CCSD-coded genetic test claims without the back-and-forth

Pabau's billing tools help UK private practices attach the right CCSD code to a patient record, track pre-authorization, and manage a claim from submission through to reconciliation, all from the same system used to record the clinical note.

Book a demo

Submitting a CCSD code 0037G claim, step by step

Most UK private practices submit CCSD-coded claims electronically through Healthcode, which runs a series of validation checks before a claim ever reaches the insurer. Knowing what those checks look for cuts down on submissions that get bounced before they’re even reviewed.

1. Confirm the code is current: Log in to the CCSD schedule and verify that 0037G is active and that its narrative matches the Mdm2 gene amplification test performed. Retired or amended codes will reject on submission.
2. Load it into your test code table: Add the code and its verified description to your practice management system exactly as the schedule states it, without abbreviating.
3. Check the insurer’s rules: Confirm the code is reimbursable under the patient’s specific policy and that pre-authorization has been obtained where required.
4. Complete the clinical record: Make sure every item in the documentation list above is on file before you generate the invoice.
5. Submit electronically: Transmit the claim through Healthcode or your practice management system’s billing module, including the membership number, authorization reference, and requesting clinician’s details.
6. Track and reconcile: Monitor the claim status and respond promptly to any insurer query. A delayed response is often what turns a query into a rejection.

Practice management software like Pabau supports this workflow directly, keeping CCSD-coded invoices, clinical records, and submission tracking in one system rather than three separate ones.

Common reasons 0037G claims bounce back

Why do genetic pathology claims get queried more often than a routine procedure code? Usually because of the same handful of gaps, repeated across different practices:

• Missing pre-authorization: The insurer required prior approval and none was obtained before the sample was collected. Check the authorization letter before the referral, not after.
• Incorrect or missing GMC/GDC number: Claims submitted without a valid registration number for the requesting clinician are routinely rejected, whether the test is billed alone or alongside other codes.
• Test narrative mismatch: The lab report’s wording doesn’t match the CCSD code’s description. Insurers cross-reference the two, and any discrepancy triggers a query.
• Bundling errors: 0037G is submitted alongside another pathology code that the CCSD coding principles treat as inclusive, meaning only one code should have been billed for that session.
• Late submission: Most insurers set a defined window after the date of service. Claims submitted outside it are often rejected with no right of appeal.
• Lapsed membership: The patient’s private medical insurance policy wasn’t active on the date the sample was taken. A quick membership check ahead of the appointment avoids this entirely.

Practices using structured digital client records catch most of these before submission, because the required fields sit inside the workflow rather than getting filled in after the fact.

Conclusion

The pattern with CCSD code 0037G is the same one that runs through every pathology code on the schedule: confirm the code and its current wording, secure pre-authorization before the sample is taken, and back the claim with documentation that matches the lab report word for word. Skip any one of those steps and the rejection risk climbs, regardless of what billing software sits behind the claim.

Pabau’s claims management software keeps CCSD code selection, clinical documentation, and claim tracking inside the same workflow used to record the patient’s visit, so nothing has to be re-entered or chased down separately. Book a demo to see how it handles CCSD billing for your practice.

Continue your research

Ordering another genetic pathology test? 0011G explains how FAP genetic analysis is classified and billed under the same schedule.

Monitoring a blood cancer for genetic relapse markers? 0040G covers MRD genomic sequencing and how it fits into the same pathology billing workflow.

Billing a lymphoma or myeloma gene rearrangement test? 0042G covers the CCND1 t(11;14) genetic test and its documentation requirements.

Billing a hepatitis B resistance test? 0504G covers the YMDD mutation test, another genetic analysis billed through the same pathology schedule.

Frequently asked questions